Detroit, MINCT03850418Now EnrollingIRB Ready

Myeloid Malignancy Clinical Trial in Detroit, MI

Access cutting-edge myeloid malignancy treatment through this clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Henry Ford Health System

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access myeloid malignancy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myeloid malignancy treatment provided free

Apply for This Detroit Location

Check if you qualify for this myeloid malignancy clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Myeloid Malignancy Study in Detroit

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Sponsor: Henry Ford Health System

Who Can Participate

Inclusion Criteria

Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor chimerism is below 98% without concurrent hematologic relapse (that is, patients with \<5% bone marrow blasts as obtained at that time point) will be offered treatment with azacitidine
\>=30 -180 days post SCT and patients must have ANC\> 1000, PLT \> 50,000
Age 18-75 years old
Performance score of at least 70% by Karnofsky
Adequate kidney and liver function as demonstrated by:
Creatinine clearance should be \>60 ml/min
Total Bilirubin \<1.5, ALT/AST/Alk Phos \< 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.
Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.
Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.
Patients must be off any prior chemotherapy, radiotherapy, or other investigational therapy within 2 weeks prior to start treatment

Exclusion Criteria

Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause
Active or prior CNS leukemia, unless in complete remission for at least 2 months.
History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.
Uncontrolled infection
Grade III, IV graft versus host disease (GVHD

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT03850418) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myeloid Malignancy Treatment Options in Detroit, MI

If you're searching for myeloid malignancy treatment options in Detroit, MI, this clinical trial (NCT03850418) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myeloid malignancy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myeloid malignancy clinical trials near you to find additional studies recruiting in your area.

More Osteogenesis Imperfecta Trials in Detroit, MI

See all osteogenesis imperfecta clinical trials recruiting in Detroit — not just this study.

Browse Osteogenesis Imperfecta Trials in Detroit →

Browse More Trials by Condition

Osteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI